Advertisement
Organisation › Details
Foresite Capital Management LLC
https://www.foresitecapital.com
LinkedIn: https://www.linkedin.com/company/foresite-capital-management
Foresite Capital is a multi-stage healthcare and life sciences investment firm with $2 billion in assets under management. The firm seeks to address areas of great unmet medical need by funding and supporting transformative healthcare businesses. Foresite Capital has a uniquely collaborative investment model that benefits from insights generated by its multidisciplinary team of scientists, clinicians, investment analysts and engineers. It applies a rigorous scientific and data-driven approach to investment analysis. Foresite Capital understands the unique business models in healthcare and works closely with the firm’s portfolio companies at all stages of their lifecycle. The firm has offices in San Francisco and New York. *
Start | 2016-03-17 existent | |
Industry | finance | |
Industry 2 | venture capital | |
Person | Tananbaum, James (Jim) (Foresite Capital 201609 CEO + Managing Director + Co-Founder) | |
Person 2 | Rome, Michael (Foresite Capital 201912 Partner) | |
Region | San Francisco, CA | |
Country | United States (USA) | |
Street | 600 Montgomery Street Suite 4500 | |
City | 94111 San Francisco, CA | |
Tel | +1-415-877-4887 | |
Address record changed: 2024-01-05 | ||
Basic data | Employees | n. a. |
Currency | USD | |
Annual sales | 2,000,000,000 (capital under management (2018) 2018-12-10) | |
* Document for »About Section«: Genomics plc. (12/10/18). "Press Release: Genomics plc Today Announces Second Close of Its Series B Financing, Raising a further £8 Million, Bringing the Total Round to £33 million ". Oxford. | ||
Record changed: 2024-01-03 |
Advertisement
More documents for Foresite Capital Management LLC
- [1] Evonetix Ltd.. (2/7/23). "Press Release: Evonetix Closes $24 Million USD (£20 Million) Financing. Oversubscribed Round Led by Foresite Capital". Cambridge....
- [2] Remix Therapeutics, Inc.. (12/8/20). "Press Release: Remix Therapeutics Launches with $81 Million Financing to Develop Small Molecule Therapies Designed to Reprogram RNA Processing". Cambridge, MA....
- [3] Bit Bio Ltd.. (6/13/20). "Press Release: Bit Bio Secures $41.5m of Funding from Top Life Sciences Investors". Cambridge....
- [4] Evonetix Ltd.. (3/2/20). "Press Release: Evonetix Raises $30 Million USD (£23 Million GBP)". Cambridge....
- [5] GenapSys Inc.. (11/20/19). "Press Release: GenapSys Raises $90M Series C Led by Foresite Capital to Commercialize Its Breakthrough Electronic Gene Sequencer". Redwood City, CA....
- [6] Element Biosciences, Inc.. (6/18/19). "Press Release: Element Biosciences Secures $15 Million Series A Financing Led by Foresite Capital and Venrock". San Diego, CA....
- [7] Genomics plc. (12/10/18). "Press Release: Genomics plc Today Announces Second Close of Its Series B Financing, Raising a further £8 Million, Bringing the Total Round to £33 million ". Oxford....
- [8] Fulcrum Therapeutics, Inc.. (9/5/18). "Press Release: Fulcrum Therapeutics Announces $80 Million Series B Financing". Cambridge, MA....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top